EVO

Evotec SEA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.80

+62.7% vs current

Most likely

Base case

45%

Probability

Target price

$3.00

+1.7% vs current

B-

Bear case

30%

Probability

Target price

$2.00

-32.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

The refreshed primary-source read argues for a cautious monitoring stance rather than a bullish turn. Evotec now has confirmed company-source catalysts, but they are mostly execution checkpoints around restructuring, cash realization, and partner-driven milestones rather than clean self-help growth inflections. With deterministic evidence quality initially very weak and management calling 2026 a transition year, sentiment looks neutral-to-cautious despite nontrivial upside if Horizon and portfolio monetization land on schedule.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventQ2 2026 Tubulis/Gilead closing could add upfront cash and sharpen balance-sheet focusHigh impact

Evotec said it expects about $100 million of upfront consideration from Tubulis' sale to Gilead, with closing anticipated in Q2 2026 subject to customary conditions; if completed on time, that would provide a concrete liquidity and portfolio-monetization proof point during an otherwise transitional year [#8K-2026-04-08].

2026-09-30catalystHorizon restructuring needs visible 2H 2026 execution to earn a reratingHigh impact

Management's March 10, 2026 Horizon plan targets a streamlined 10-site footprint, up to 800 position reductions, and about €75 million of run-rate savings by end-2027, with first operational and financial effects expected in 2H 2026; failure to show early margin or commercial-execution benefits would likely keep the stock in monitoring mode [#PR-2026-03-10][#8K-2026-04-08].

2027-03-31catalystPartnered-program milestones remain the main upside lever but timing is still looseHigh impact

Evotec confirmed BMS-986506 moved into Phase 1 in March 2026 with a $10 million milestone, and its April results release also highlighted continued BMS neuroscience progress and Bayer's Phase 2 start in Alport syndrome; additional clinical or milestone progress could revalue the partnered-asset narrative, but near-term timing remains uncertain [#PR-2026-03-19][#8K-2026-04-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology